- Home
- NVGS vs RCUS Comparison
NVGS vs RCUS Comparison
Compare NVGS & RCUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NVGS
- RCUS
- Stock Information
- Founded
- NVGS 1997
- RCUS 2015
- Country
- NVGS United Kingdom
- RCUS United States
- Employees
- NVGS N/A
- RCUS N/A
- Industry
- NVGS Marine Transportation
- RCUS Biotechnology: Pharmaceutical Preparations
- Sector
- NVGS Consumer Discretionary
- RCUS Health Care
- Exchange
- NVGS Nasdaq
- RCUS Nasdaq
- Market Cap
- NVGS 1.1B
- RCUS 1.2B
- IPO Year
- NVGS N/A
- RCUS 2018
- Fundamental
- Price
- NVGS $16.33
- RCUS $20.29
- Analyst Decision
- NVGS Strong Buy
- RCUS Buy
- Analyst Count
- NVGS 3
- RCUS 8
- Target Price
- NVGS $22.33
- RCUS $27.25
- AVG Volume (30 Days)
- NVGS 337.8K
- RCUS 1.4M
- Earning Date
- NVGS 11-04-2025
- RCUS 10-28-2025
- Dividend Yield
- NVGS 1.23%
- RCUS N/A
- EPS Growth
- NVGS 12.51
- RCUS N/A
- EPS
- NVGS 1.26
- RCUS N/A
- Revenue
- NVGS $566,889,000.00
- RCUS $240,000,000.00
- Revenue This Year
- NVGS $1.63
- RCUS N/A
- Revenue Next Year
- NVGS $2.78
- RCUS N/A
- P/E Ratio
- NVGS $12.98
- RCUS N/A
- Revenue Growth
- NVGS 1.19
- RCUS N/A
- 52 Week Low
- NVGS $10.55
- RCUS $6.50
- 52 Week High
- NVGS $17.53
- RCUS $22.11
- Technical
- Relative Strength Index (RSI)
- NVGS 64.91
- RCUS 75.10
- Support Level
- NVGS $14.74
- RCUS $16.41
- Resistance Level
- NVGS $15.34
- RCUS $18.42
- Average True Range (ATR)
- NVGS 0.34
- RCUS 1.38
- MACD
- NVGS 0.20
- RCUS 0.25
- Stochastic Oscillator
- NVGS 94.14
- RCUS 76.82
About NVGS Navigator Holdings Ltd. (Marshall Islands)
Navigator Holdings Ltd owns and operates liquefied gas carriers, which include a fleet of handysize liquefied gas carriers. The company also owns a share in an ethylene export marine terminal at Morgan's Point, Texas on the Houston Ship Channel (the Ethylene Export Terminal) through a joint venture (the Export Terminal Joint Venture). Company play a vital role in theglobalised liquefied gas supply chain, providing gas transportation solutions for energy companies, industrial users and commodity traders.
About RCUS Arcus Biosciences Inc.
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.